TEL
AVIV, Israel, July 22,
2024 /PRNewswire/ -- CannaMore Biotechs, an
Israel-based clinical-stage
company focused on Cannabidiol (CBD) based treatments, is
pleased to announce the successful completion of its Phase 2a
clinical trial evaluating the safety and efficacy of a CBD-based
patent protected formulation for patients with Ulcerative Colitis
(UC).
The trial is an open-label, single-arm study, aimed to assess
the safety, tolerability, and efficacy of the CBD-based IP-based
enema formulation, IcBD-01, as a potential treatment for UC.
Conducted over a three-month period, the study included 10 patients
who completed the trial, with promising results observed in the
majority of participants.
Key highlights from the trial include:
- Primary Endpoint Achieved: A significant number of
patients demonstrated a reduction in Mayo scores, indicating a
decrease in disease severity.
- Patient-Reported Outcomes (PRO): Most participants
reported substantial improvements in their symptoms, including
reduced abdominal pain and better overall well-being.
- Safety and Tolerability: The formulation was
well-tolerated with no significant side effects observed,
confirming the safety profile of IcBD-01.
Prof. Timna Naftali, a specialist
in gastroenterology at Meir Hospital in Kfar Saba, led the study,
which was conducted at the Israeli medical facilities of leading
Hospital Meir at Kfar Saba, Israel. Meir Hospital is one of the 14
full-scale hospitals of Clalit Health Services, the 2nd largest HMO
in the world and CannaMore's partner through Mor Research
Applications TTO.
"The results of this trial are highly encouraging and support
the potential of IcBD-01 as an effective treatment for Ulcerative
Colitis," said Prof. Naftali. "We observed significant improvements
in both clinical outcomes and patient-reported symptoms, which
marks a promising step forward in our ongoing efforts to develop
innovative CBD-based therapies. This treatment may provide a safe
and effective solution for the subgroup of patients with ulcerative
proctitis, where there is an unmet need for effective and safe
treatment."
Based on these positive outcomes, CannaMore Biotechs plans to
both advance to the next stage of clinical trials to further
evaluate the long-term efficacy and safety of IcBD-01, while also
exploring more immediate non-drug markets (such as medical Cannabis
and others) sales in parallel to the drug R&D aimed for an FDA
approval.
About CannaMore Biotechs Ltd.
CannaMore Biotechs Ltd. is a company dedicated to the
simultaneous independent research and development of
cannabinoid-based pharmaceutical drugs for various indications.
Backed by a partnership with Mor Research Applications, the
technology transfer company of Clalit Health Services, CannaMore
leverages cutting-edge research to bring innovative treatments to
patients in need. As a clinical research platform, CannaMore run
multiple potential projects, with IcBD in colitis as the leading
flagship, CannaMore is at the forefront of cannabinoid-based
medical advancements.
For further information, contact
info@cannamorebio.com.
View original
content:https://www.prnewswire.com/news-releases/cannamore-biotechs-announces-successful-completion-of-phase-2a-clinical-trial-for-cannabidiol-based-treatment-for-ulcerative-colitis-302202525.html
SOURCE CannaMore Biotechs